Pharmacokinetic Drug Interaction Between Revaprazan and Itopride HCl in Healthy Male Subjects
NCT01332890 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2014-07-10
Summary
To evaluate drug-drug interaction
Conditions
- Healthy
Interventions
- OTHER
-
Sequence 1
Period1(A) Period2(B) Period3(C) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
- OTHER
-
Sequence 2
Period1(C) Period2(A) Period3(B) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
- OTHER
-
Sequence 3
Period1(B) Period2(C) Period3(A) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
- OTHER
-
Sequence 4
Period1(C) Period2(B) Period3(A) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
- OTHER
-
Sequence 5
Period1(B) Period2(A) Period3(C) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
- OTHER
-
Sequence 6
Period1(A) Period2(C) Period3(B) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
Sponsors & Collaborators
-
Yuhan Corporation
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 20 Years
- Max Age
- 50 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2011-04-30
- Primary Completion
- 2011-08-31
- Completion
- 2011-08-31
Countries
- South Korea
Study Locations
More Related Trials
-
A Clinical Trial to Evaluate Drug-drug Interactions and Safety Between "BR1015-1" and "BR1015-2" in Healthy Volunteers
NCT05097794 ·Status: COMPLETED ·Phase: PHASE1
-
A Drug Interaction Study of Mosapride and Rebamipide
NCT02106130 ·Status: COMPLETED ·Phase: PHASE1
-
Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects
NCT06119958 ·Status: RECRUITING ·Phase: PHASE1
-
A Clinical Trial Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1019-1 and BR1019-2 in Healthy Adult Subjects
NCT05875259 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Drug-drug Interactions Between BR1017-1 and BR1017-2 in Healthy Volunteers
NCT05372380 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating a Pharmacokinetic Drug Interaction Between HGP0918 and HGP0816
NCT02554136 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Drug Interactions Between HGP1607 and HGP1501
NCT03089112 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy Volunteers
NCT06636877 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Drug Interaction Study Between Gemigliptin and Irbesartan After Oral Administration in Healthy Male Subjects
NCT01825850 ·Status: COMPLETED ·Phase: PHASE1
-
Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers
NCT02248259 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs
NCT02641899 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930
NCT05207761 ·Status: COMPLETED ·Phase: PHASE1
-
Drug Interaction and Safety Between Valsartan and Rosuvastatin in Healthy Male Volunteers
NCT01918709 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Study of Levocetirizine Oral Solution
NCT01622283 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2"
NCT06226727 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Bosentan After Oral Administration
NCT01929213 ·Status: UNKNOWN ·Phase: PHASE1
-
Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-B
NCT06618079 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Pharmacokinetic Interactions Between Atorvastatin and Metformin in Healthy Male Subjects
NCT01765023 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy
NCT06220773 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Investigate Drug-Drug Interaction Between D326, D337 and CKD-828 in Healthy Subjects
NCT03726866 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study to Evaluate Pharmacokinetic/Pharmacodynamic Drug-drug Interaction and Safety/Tolerability Between RLD2202 and RLD2203
NCT05481307 ·Status: COMPLETED ·Phase: PHASE1
-
Investigate a Pharmacokinetic Characteristics and the Safety of AG1502 in Healthy Male Subjects
NCT02614352 ·Status: UNKNOWN ·Phase: PHASE1
-
Pharmacokinetic Interactions in Combination Treatment of Valproic Acid and Ertapenem in Normal Subjects
NCT01073059 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Drug Interaction Between Candesartan and Rosuvastatin
NCT02079506 ·Status: COMPLETED ·Phase: PHASE1
-
Phamacokinetics and Safety Profiles of DA-5213 10mg in Healthy Subjects
NCT05106205 ·Status: COMPLETED ·Phase: PHASE1